Skip to main content Accessibility help
×
Home
  • Print publication year: 2004
  • Online publication date: August 2009

14 - Diagnosis and treatment of osteoporosis

from Part III - Disease prevention

Summary

Osteoporosis is a major public health problem, affecting more than 40 million people, one-third of postmenopausal women, and a substantial portion of the elderly in the USA, Europe, and Japan. The risk factors for osteoporosis such as sedentary lifestyle and/or immobility, low bodyweight, cigarette smoking, and excessive alcohol consumption all influence bone mass negatively. The history and physical examination are important in screening for secondary forms of osteoporosis and directing the evaluation, although they are neither sensitive enough nor sufficient for diagnosing primary osteoporosis. The most widely used techniques of assessing bone mineral density are dual-energy X-ray absorptiometry (DEXA) and quantitative computerized tomography (CT). Treatment for osteoporosis is instituted to prevent early or continuing bone loss, with the belief that there can be an immediate impact on the patient's wellbeing and a willingness to comply with the patient's desires.
REFERENCES
Melton, L. J.How many women have osteoporosis?J. Bone Miner. Res. 1992; 7:1005–10
Cooper, C. and Melton, L. J., III. Epidemiology of osteoporosis. Trends Endocrinol. Metab. 1992; 314:224–9
www.nof.org/osteoporosis/stats.htm. Accessed March 2003
Taxel, P.Osteoporosis: detection, prevention, and treatment in primary care. Geriatrics 1998; 53:22–33
Finkelstein, J. S., Sowers, M., Greendale, D. A., et al.Ethnic variation in bone turnover in pre- and early perimenopausal women: effects of anthropometric and lifestyle factors. J. Clin. Endocrinol. Metab. 2002;. 87:3051–6
Cadogen, J.Eastell, R., Jones, N. and Barker, M. E.Milk intake and bone mineral acquisition in adolescent girls: randomised, controlled intervention trial. Br. Med. J. 1997; 315:1255–60
Eisman, J.Relevance of pregnancy and lactation to osteoporosis. Lancet 1998; 352:504–5
Hotta, M., Shibasaki, T., Sato, K. and Demura, H.The importance of body weight history in the occurrence and recovery of osteoporosis in patients with anorexia nervosa: evaluation by dual x-ray absorptiometry and bone metabolic markers. Eur. J. Endocrinol. 1998; 139:276–83
Ernst, E.Exercise for female osteoporosis. A systematic review of randomised clinical trials. Sports Med. 1998; 25:359–68
Dalsky, G. P., Stocke, K. S., Ehsani, A. A., et al.Weight-bearing exercise training and lumbar bone mineral content in postmenopausal women. Ann. Intern. Med. 1988; 108:824–8
Chow, R., Harrison, J. E. and Notarius, C.Effect of two randomized exercise programs on bone mass of healthy postmenopausal women. Br. Med. J. 1987; 295:1441–4
Kohrt, W. M., Snead, D. B., Slatopolsky, E. and Birge, S. J.Additive effects of weight-bearing exercise and estrogen on bone mineral density in older women. J. Bone Miner. Res. 1995; 10:1303–11
Nelson, M. E., Fiatarone, M. A., Morganti, C. M., et al.Effects of high-intensity strength training on multiple risk factors for osteoporotic fractures. J. Am. Med. Assoc. 1994; 272:1909–14
Henderson, N. K., White, C. P. and Eisman, J. A.The role of exercise and fall risk reduction in the prevention of osteoporosis. Endocrinol. Metab. Clin. North Am. 1998; 27:369–87
Drinkwater, B. L.Physical exercise and bone health. J. Am. Med. Womens Assoc. 1990; 45:91–97
Kroger, H. and Reeve, J.Diagnosis of osteoporosis in clinical practice. Ann. Med. 1998; 30:278–87
World Health Organization. Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis: Report of a WHO Study Group. Geneva: WHO; 1994
Arnaud, C. D.Osteoporosis: using “bone markers” for diagnosis and monitoring. Geriatrics 1996: 51:24–30
Genant, H. K.Current state of bone densitometry for osteoporosis. Radiographics 1998; 18:913–18
Blake, G. M. and Fogelman, I.Applications of bone densitometry for osteoporosis. Endocrinol. Metab. Clin. North Am. 1998; 27:267–88
Scientific Advisory Board, Osteoporosis Society of Canada. Clinical practice guidelines for the diagnosis and management of osteoporosis. Can. Med. Assoc. J. 1996; 155:1113–33
US Preventive Services Task Force. Guide to Clinical Preventive Services. Baltimore, MD: Williams & Wilkins; 1996
Umland, E. M., Rinaldi, C., Parks, S. M. and Boyce, E. G.The impact of estrogen replacement therapy and raloxifene on osteoporosis, cardiovascular disease, and gynecologic cancers. Ann. Pharmacother. 1999; 33:1315–28
Ravn, P., Bidstrup, M., Wasnich, R. D.et al.Alendronate and estrogen–progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study: a randomized trial. Ann. Intern. Med. 1999; 131:935–42
Roussouw, J., Anderson, G. L., Prentice, R. L., et al.Risks and benefits of estrogen plus progestin in healthy postmenopausal women. J. Am. Med. Assoc. 2002; 288: 32–33
Colditz, G. A., Hankinson, S. E., Hunter, D. J., et al.The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N. Engl. J. Med. 1995; 332:1589–93
Reid, I. R.The role of calcium and vitamin D in the prevention of osteoporosis. Endocrinol. Metab. Clin. North Am. 1998; 27:389–98
Aloia, J. F., Vaswani, A., Yeh, J. K., et al.Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss. Ann. Intern. Med. 1994; 114:97–103
Reid, I. R.The role of calcium and vitamin D in the prevention of osteoporosis. Endocrinol. Metab. Clin. North. Am. 1998; 27:389–98
Avioli, L. V.The role of calcitonin in the prevention of osteoporosis. Endocrinol. Metab. Clin. North. Am. 1998; 27:411–18
Overgaard, K., Hansen, M. A., Jansen, S. B. and Christiansen, C.Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose response study. Br. Med. J. 1992; 305:556–61
Chestnut, C. H., Silverman, S. L., Adriano, K., et al.Salmon-calcintonin nasal spray prevents vertebral fractures in established osteoporosis. Final world wide results of the “PROOF”. Calcif. Tissue Int. 1999; 64 (supp 1):1–26
Watts, N. B.Treatment of osteoporosis with bisphosphonates. Endocrinol. Metab. Clin. North. Am. 1998; 27:419–39
Devogelaer, J. P. Arisk–benefit assessment of alendronate in the treatment of involutional osteoporosis. Drug Saf. 1998; 19:141–54
Black, D. M., Cummings, S. R., Karpf, D. B., et al.Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348:1535–41
Saag, K. G., Enkey, R., Schnitzer, T. J., et. alAlendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N. Engl. J. Med. 1998; 339: 292–9
Reginster, J. Y., Minne, H. W., Sorensen, O. H., et al.Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos. Int. 2000; 11:83–91
Harris, S. T., Watts, N. B., Genant, H. K., et al.Effects of residronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. J. Am. Med. Assoc. 1999; 282:1344–52
McClung, M.Therapy for fracture prevention. J. Am. Med. Assoc. 1999; 282; 687–9
Kreig, M. A., Seydoux, C., Sandini, L., et al.Intravenous pamidonate as treatment for osteoporosis after heart transplantation: a prospective study. Osteoporos. Int. 2001; 12: 112–16
Delmas, P. D., Bjarnason, N. H., Mitlak, B. H., et al.Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N. Engl. J. Med. 1997; 337:1641–7
Draper, M. W., Flowers, D. E., Huster, W. J., et al.A controlled trial of raloxifene HCL: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J. Bone. Miner. Res. 1996; 11:835–42
Willhite, S. L., Goebel, S. R. and Scoggin, J. A.Raloxifene provides an alternative for osteoporosis prevention. Ann. Pharmacother. 1998; 32:834–7
Ettinger, B., Black, D. M., Mitlak, B. H., et al.Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. results from a 3 year randomized clinical trial.”J. Am. Med. Assoc. 1999; 282:637–45
Fugh-Berman, A.Progesterone cream for osteoporosis. Altern. Ther. Womens Health 1999; 1:33–40
Potter, S. M., Baum, J. A., Teng, H., et al.Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am. J. Clin. Nutr. 1998; 68(supp):1375–9
Israel, E., Banerjee, T. R., Fitzmaurice, G. M., et al.Effects of inhaled glucocorticoids on bone density in premenopausal women. N. Engl. J. Med. 1401; 345:941–7.